



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock code: 8329)

**ANNOUNCEMENT ON THE THIRD QUARTERLY RESULTS
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2012**

**CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK
EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE"):**

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from, or in reliance upon, the whole or any part of the contents of this announcement.

This announcement, for which the directors (the "Directors") of Shenzhen Neptunus Interlong Bio-technique Company Limited (the "Company") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

QUARTERLY RESULTS (UNAUDITED)

The board of Directors (the "Board") of the Company is pleased to present the unaudited condensed consolidated financial statements of the Company and its subsidiaries, (collectively the "Group") for the nine months ended 30 September 2012 (the "Relevant Period"), together with the unaudited comparative figures for the corresponding period of 2011.

CONDENSED CONSOLIDATED INCOME STATEMENT (UNAUDITED)

For the three months and nine months ended 30 September 2012

		For the three months ended 30 September (Unaudited)		For the nine months ended 30 September (Unaudited)	
	Note	2012 RMB'000	2011 RMB'000	2012 RMB'000	2011 RMB'000
CONTINUING OPERATIONS					
TURNOVER	4	132,655	123,606	405,522	364,321
Cost of sales		(90,282)	(81,217)	(255,268)	(238,382)
Gross profit	4	42,373	42,389	150,254	125,939
Other revenue	4	2,656	1,678	9,877	6,776
Other net income	4	–	423	1,073	1,010
Selling and distribution expenses		(18,424)	(15,986)	(50,533)	(43,760)
Administrative expenses		(11,940)	(11,654)	(33,836)	(34,138)
Other operating expenses		(6,036)	(8,965)	(22,147)	(16,555)
PROFIT FROM OPERATIONS		8,629	7,885	54,688	39,272
Finance costs	6	(1,566)	(3,431)	(4,736)	(10,933)
PROFIT BEFORE TAXATION	5	7,063	4,454	49,952	28,339
Income tax	7	(2,400)	(1,879)	(12,238)	(10,396)
PROFIT FROM CONTINUING OPERATIONS FOR THE PERIOD		4,663	2,575	37,714	17,943
DISCONTINUED OPERATIONS					
Profit from discontinued operations	9	–	19,276	–	12,562
PROFIT FOR THE PERIOD		4,663	21,851	37,714	30,505

CONDENSED CONSOLIDATED INCOME STATEMENT (UNAUDITED)

For the three months and nine months ended 30 September 2012

	Note	For the three months ended 30 September (Unaudited)		For the nine months ended 30 September (Unaudited)	
		2012 RMB'000	2011 RMB'000	2012 RMB'000	2011 RMB'000
Attributable to:					
Owners of the Company		3,169	20,539	28,657	24,295
Non-controlling interests		1,494	1,312	9,057	6,210
		4,663	21,851	37,714	30,505
EARNINGS PER SHARE					
From continuing and discontinued operations					
Basic and diluted	10	RMB0.19 cents	RMB1.22 cents	RMB1.71 cents	RMB1.45 cents
From continuing operations					
Basic and diluted	10	RMB0.19 cents	RMB0.08 cents	RMB1.71 cents	RMB0.70 cents

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)

For the three months and nine months ended 30 September 2012

	For the three months ended 30 September (Unaudited)		For the nine months ended 30 September (Unaudited)	
	2012	2011	2012	2011
	RMB'000	RMB'000	RMB'000	RMB'000
Profit for the period	4,663	21,851	37,714	30,505
Other comprehensive income for the period				
Other comprehensive income for the period, net of tax	—	4,155	—	4,155
Total other comprehensive income for the period, net of tax	—	—	—	—
Total comprehensive income for the period	4,663	26,006	37,714	34,660
Total comprehensive income attributable to:				
Owners of the Company	3,169	24,694	28,657	28,450
Non-controlling interests	1,494	1,312	9,057	6,210
	4,663	26,006	37,714	34,660

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

For the nine months ended 30 September 2012

	Attributable to owners of the Company						Non-controlling interests	Total equity
	Issued share capital	Share premium	Capital reserve	Statutory reserve fund	Exchange reserve	Accumulated loss		
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2011	167,800	554,844	(194,339)	8,302	(4,155)	(141,610)	390,842	455,868
Changes in equity for 2011								
Profit for the period	–	–	–	–	–	24,295	24,295	30,505
Other comprehensive income, net of tax	–	–	–	–	4,155	–	4,155	4,155
Total comprehensive income for the period, after tax	–	–	–	–	4,155	24,295	28,450	34,660
Dividend paid from subsidiary to non-controlling interests	–	–	–	–	–	–	(3,000)	(3,000)
Acquisition of non-controlling interests in subsidiary	–	–	–	–	–	(10)	(10)	(200)
At 30 September 2011	<u>167,800</u>	<u>554,844</u>	<u>(194,339)</u>	<u>8,302</u>	<u>–</u>	<u>(117,325)</u>	<u>419,282</u>	<u>487,328</u>
At 1 January 2012	167,800	554,844	(194,339)	12,276	–	(123,908)	416,673	486,276
Changes in equity for 2012								
Profit for the period	–	–	–	–	–	28,657	28,657	37,714
Other comprehensive income, net of tax	–	–	–	–	–	–	–	–
Total comprehensive income for the period, after tax	–	–	–	–	–	–	–	–
Dividend paid from subsidiary to non-controlling interests	–	–	–	–	–	–	(4,000)	(4,000)
At 30 September 2012	<u>167,800</u>	<u>554,844</u>	<u>(194,339)</u>	<u>12,276</u>	<u>–</u>	<u>(95,251)</u>	<u>445,330</u>	<u>519,990</u>

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate information

The Company is a joint stock limited company registered in the People's Republic of China (the "PRC"). The registered office of the Company is located at 1st Floor, Block 1, Research Building, Neptunus Technical Center, Langshan 2nd R.N., Nanshan District, Shenzhen, Guangdong Province, the PRC.

2. Basis of preparation and accounting policies

The unaudited condensed consolidated financial statements for the nine months ended 30 September 2012 have been prepared in accordance with the applicable disclosure provision of the GEM Listing Rules of the Stock Exchange, including compliance with Hong Kong Accounting Standard ("HKAS") 34, "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA").

The preparation of the unaudited condensed consolidated financial statements in conformity with HKAS 34 requires the management to make judgements, estimates and assumptions that affect the application of policies and the reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

The unaudited condensed consolidated financial statements have been prepared in accordance with the same accounting policies adopted in the annual financial statements for the year ended 31 December 2011, except for the adoption of the new Hong Kong Financial Reporting Standards ("HKFRSs") and Hong Kong Accounting Standards ("HKASs"). The condensed consolidated financial statements do not include all the information and disclosures required for an annual financial statements, and should be read in conjunction with the financial statements of the Group for the year ended 31 December 2011.

The HKICPA has issued a number of new and revised HKFRSs and Interpretations that are first effective or available for early adoption for the current accounting period of the Company. There have been no significant changes to the accounting policies applied in these financial statements for the periods as a result of these developments.

This unaudited condensed consolidated interim financial information for the period ended 30 September 2012 comprise the Company and its subsidiaries. The measurement basis used in the preparation of the financial statements is the historical cost basis. These financial statements are presented in Renminbi ("RMB"), which is also the functional currency of the Company and all amounts are rounded to the nearest thousand except where otherwise indicated.

The condensed consolidated financial statements of quarterly financial information is unaudited.

3. Segment Reporting

The Group manages its businesses by divisions which are organised by a mixture of both business lines (products and services) and geography. In a manner consistent with the way in which information is reported internally to the Group's executive directors for the purpose of resource allocation and performance assessment, the Group has identified the following two reportable segments. No operating segments have been aggregated to form the following reportable segments.

- (i) Manufacturing and selling of medicine products
- (ii) Provision of R&D services of modern biological technology

Currently all the above Group's activities are carried out in the PRC. No reportable operating segment has been aggregated.

The medical products segment derives its revenue from manufacture and sale of medical products.

The R&D services segment derives its revenue from the provision of R&D services income.

(a) Segment results, assets and liabilities

For the purposes of assessing segment performance and allocating resources between segments, the Group's executive directors monitors the results, assets and liabilities attributable to each reportable segment on the following bases:

Segment assets include all tangible, intangible assets and current assets with the exception of deferred tax assets and other corporate assets. Segment liabilities include segmental business payables attributable to the activities of the individual segments and bank borrowings managed directly by the segments. Revenue and expenses are allocated to the reportable segments with reference to sales generated by those segments and the expenses incurred by those segments or which otherwise arise from the depreciation or amortisation of assets attributable to those segments. The measure used for reporting segments profit is "adjusted EBITDA" i.e. "adjusted earnings before interest, taxes, depreciation and amortisation", where "interest" is regarded as including investment income and "depreciation and amortisation" is regarded as including impairment losses on non-current assets. To arrive at adjusted EBITDA the Group's earnings are further adjusted for items not specifically attributed to individual segments, such as directors' and auditors' remuneration and other head office or corporate administration costs. In addition to receiving segment information concerning adjusted EBITDA, management is provided with segment information concerning revenue (including inter-segment sales), interest income and expense from cash balances and borrowings managed directly by the segments, depreciation, amortisation and impairment losses and additions to noncurrent segment assets used by the segments in their operations. Intersegment sales are priced with reference to prices charged to external parties for similar orders.

Information regarding the Group's reportable segments as provided to the Group's executive directors for the purposes of resource allocation and assessment performance for the period ended 30 September 2012 and 2011 is set out below:

The operation in a jointly controlled entity was discontinued in 2011, the segment information reported on the followings does not include any amounts for the discontinued operation.

For the nine months ended 30 September	Continuing operations					
	Manufacturing and selling of pharmaceutical products		R&D service		Total	
	2012	2011	2012	2011	2012	2011
	(Unaudited) RMB'000	(Unaudited) RMB'000	(Unaudited) RMB'000	(Unaudited) RMB'000	(Unaudited) RMB'000	(Unaudited) RMB'000
Segment revenue						
Revenue from external customers	405,522	362,321	–	2,000	405,522	364,321
Inter-segment revenue	–	–	–	–	–	–
Reportable segment	<u>405,522</u>	<u>362,321</u>	<u>–</u>	<u>2,000</u>	<u>405,522</u>	<u>364,321</u>
Reportable segment profit/(loss) before taxation	<u>71,199</u>	<u>56,515</u>	<u>(10,331)</u>	<u>(7,683)</u>	<u>60,868</u>	<u>48,832</u>
Interest income from bank deposits	731	560	162	168	893	728
Interest expenses	4,621	4,137	115	6,797	4,736	10,934
Depreciation and amortisation						
– Property, plant and equipment	9,702	8,552	2,411	2,349	12,113	10,901
– Prepaid lease payment	1,178	1,178	–	–	1,178	1,178
– Intangible assets	3,200	3,928	6	16	3,206	3,944
Reversal of impairment on trade receivables	(1,073)	(587)	–	(423)	(1,073)	(1,010)
Impairment on other receivables	33	–	–	–	33	–
Written down of inventory	436	410	–	–	436	410
Income tax expense	<u>12,238</u>	<u>10,638</u>	<u>–</u>	<u>(242)</u>	<u>12,238</u>	<u>10,396</u>

Continuing operations						
	Manufacturing and selling of pharmaceutical products		R&D service		Total	
	30 September 2012 (Unaudited) RMB'000	31 December 2011 (Unaudited) RMB'000	30 September 2012 (Unaudited) RMB'000	31 December 2011 (Unaudited) RMB'000	30 September 2012 (Unaudited) RMB'000	31 December 2011 (Unaudited) RMB'000
Reportable segment assets	727,176	584,667	220,263	174,850	947,439	759,517
Additions to non-current assets (other than financial instruments and deferred tax assets)	5,143	12,341	29,057	1,590	34,200	13,931
Reportable segment liabilities	328,756	196,594	54,602	32,123	383,358	228,717

(b) Reconciliations of reportable segment revenue, profit or loss, assets and liabilities

	Nine months ended 30 September	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Revenue		
Reportable segment revenue	405,522	364,321
Elimination of inter-segment revenue	–	–
Consolidated turnover	405,522	364,321
Profit/(loss)		
Reportable segment profit	60,868	48,832
Elimination of inter-segment profit	–	–
Reportable segment profit derived from the Group's external customers	60,868	48,832
Other revenue and other net income	10,950	7,786
Depreciation and amortisation	(16,497)	(16,023)
Finance costs	(4,736)	(10,933)
Unallocated head office and corporate expense	(633)	(1,323)
Consolidated profit before taxation	49,952	28,339

	At 30 September 2012 (Unaudited) RMB'000	At 31 December 2011 (Audited) RMB'000
Assets		
Reportable segment assets	947,439	759,517
Elimination of inter-segment receivables	(58,885)	(48)
	<u>888,554</u>	<u>759,469</u>
Unallocated head office and corporate assets	300	300
Deferred tax assets	1,563	1,548
	<u>890,417</u>	<u>761,317</u>
Liabilities		
Reportable segment liabilities	383,358	228,717
Elimination of inter-segment payables	(58,885)	(48)
	<u>324,473</u>	<u>228,669</u>
Tax payable	5,657	6,076
Deferred tax liabilities	40,296	40,296
Unallocated head office and corporate liabilities	–	–
	<u>370,426</u>	<u>275,041</u>

4. Turnover and other revenue

The Group's turnover represents the net invoiced value of the goods sold net of value-added tax ("VAT") after allowances for returns and trade discounts and net invoiced value of R&D services provided net of sale tax. An analysis of turnover and other revenue is as follows:

	For the three months ended 30 September		For the nine months ended 30 September	
	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000	2012 (Unaudited) RMB'000	2011 (Unaudited) RMB'000
Turnover				
Sale of medicines	132,655	123,606	405,522	362,321
R&D service income	–	–	–	2,000
	<u>132,655</u>	<u>123,606</u>	<u>405,522</u>	<u>364,321</u>

	Continuing operations For the three months ended 30 September		Discontinued operations For the three months ended 30 September		Consolidated For the three months ended 30 September		Continuing operations For the nine months ended 30 September		Discontinued operations For the nine months ended 30 September		Consolidated For the nine months ended 30 September	
	2012	2011	2012	2011	2012	2011	2012	2011	2012	2011	2012	2011
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Other revenue												
Exchange gain	262	–	–	–	262	–	742	–	–	–	742	–
Interest income on bank deposits	289	194	–	–	289	194	893	728	–	8	893	736
Subsidy income released from deferred revenue	2,100	1,477	–	–	2,100	1,477	8,024	5,685	–	–	8,024	5,685
Disposal of jointly controlled entity revenue	–	–	–	21,031	–	21,031	–	–	–	21,031	–	21,031
Others	5	7	–	–	5	7	218	363	–	–	218	363
	<u>2,656</u>	<u>1,678</u>	<u>–</u>	<u>21,031</u>	<u>2,656</u>	<u>22,709</u>	<u>9,877</u>	<u>6,776</u>	<u>–</u>	<u>21,039</u>	<u>9,877</u>	<u>27,815</u>
Other net income												
Reversal of impairment on trade receivables	–	423	–	–	–	423	1,073	1,010	–	–	1,073	1,010
	<u>–</u>	<u>423</u>	<u>–</u>	<u>–</u>	<u>–</u>	<u>423</u>	<u>1,073</u>	<u>1,010</u>	<u>–</u>	<u>–</u>	<u>1,073</u>	<u>1,010</u>

5. Profit before taxation

	Continuing operations For the three months ended 30 September		Discontinued operations For the three months ended 30 September		Consolidated For the three months ended 30 September		Continuing operations For the nine months ended 30 September		Discontinued operations For the nine months ended 30 September		Consolidated For the nine months ended 30 September	
	2012	2011	2012	2011	2012	2011	2012	2011	2012	2011	2012	2011
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
(a) Staff costs (including director's emoluments)												
Salaries, wages and other benefits	21,972	17,513	–	351	21,972	17,864	43,299	33,572	–	2,588	43,299	36,160
Contributions to defined contribution retirement plan	2,991	3,082	–	64	2,991	3,146	7,865	6,946	–	283	7,865	7,229
	<u>24,963</u>	<u>20,595</u>	<u>–</u>	<u>415</u>	<u>24,963</u>	<u>21,010</u>	<u>51,164</u>	<u>40,518</u>	<u>–</u>	<u>2,871</u>	<u>51,164</u>	<u>43,389</u>
(b) Other Item												
Cost of inventories	88,639	84,003	–	–	88,639	84,003	250,389	233,065	–	–	250,389	233,065
Amortisation												
– prepaid lease payments	393	393	–	35	393	428	1,178	1,178	–	247	1,178	1,425
– intangible assets*	1,227	1,955	–	–	1,227	1,955	3,206	3,944	–	–	3,206	3,944
Depreciation	3,919	2,893	–	388	3,919	3,281	12,113	10,854	–	2,427	12,113	13,281
R & D costs*	4,825	4,088	–	–	4,825	4,088	18,298	8,998	–	19	18,298	9,017
Loss on disposal of property, plant and equipment*	3	295	–	81	3	376	4	926	–	81	4	1,007
Written down of inventory*	(23)	408	–	–	(23)	408	436	410	–	–	436	410
Auditor's remuneration												
– other services	56	174	–	–	56	174	306	584	–	–	306	584
	<u>56</u>	<u>174</u>	<u>–</u>	<u>–</u>	<u>56</u>	<u>174</u>	<u>306</u>	<u>584</u>	<u>–</u>	<u>–</u>	<u>306</u>	<u>584</u>

* These amounts have been included in "Other operating expenses" in the unaudited condensed consolidated income statement.

6. Finance costs

	For the three months ended 30 September		For the nine months ended 30 September	
	2012	2011	2012	2011
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	RMB'000	RMB'000	RMB'000	RMB'000
Interest on bank loans wholly repayable within five years	841	2,089	3,403	6,043
Interest on entrusted loans from the immediate parent company	325	491	810	1,458
Interest on financial assistance from the immediate parent company	130	1,060	130	3,641
Interest on financial assistance from a fellow subsidiary	270	—	393	—
Total interest expense on financial liabilities not at fair value through profit or loss	<u>1,566</u>	<u>3,640</u>	<u>4,736</u>	<u>11,142</u>

7. Income tax

Income tax in the condensed consolidated income statement represents:

	For the three months ended 30 September		For the nine months ended 30 September	
	2012	2011	2012	2011
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	RMB'000	RMB'000	RMB'000	RMB'000
Current tax				
Provision for PRC Enterprise Income Tax	2,400	1,879	12,253	10,639
Deferred tax				
Origination and reversal of temporary differences	—	—	(15)	(243)
	<u>2,400</u>	<u>1,879</u>	<u>12,238</u>	<u>10,396</u>

Hong Kong profits tax has not been provided for as the Group had no income assessable to Hong Kong profit tax during the Relevant Period. The PRC enterprise income tax ("EIT") for the Relevant Period is 25%. A subsidiary of the Group was qualified as high-tech enterprise and is entitled to a reduction in tax rate. Accordingly, the subsidiary's EIT for the Relevant Period was provided at the rate of 15%.

8. Dividends

The Board does not recommend the payment of any dividend for the Relevant Period (2011: Nil).

9. Discontinued operation

On 13 June 2011, the Company and GlaxoSmithKline Pte Limited ("GSK") entered into the agreement pursuant to which the Company agreed to sell the 51% equity interests of Shenzhen GSK Neptunus Biologicals Co., Ltd. ("GSK-Neptunus") to GSK at the consideration of USD39,000,000, subject to the terms and conditions of the agreement. On 20 September 2011, the transaction was completed and GSK-Neptunus ceased to be a jointly controlled entity of the Company.

The last year results of the discontinued operations included in the condensed consolidated income statement, condensed consolidated statement of comprehensive income and condensed consolidated statement of cash flows are set out below.

	Note	For the three months ended 30 September (Unaudited)		For the nine months ended 30 September (Unaudited)	
		2012 RMB'000	2011 RMB'000	2012 RMB'000	2011 RMB'000
TURNOVER		–	–	–	–
Cost of sales		–	–	–	–
Gross profit		–	–	–	–
Other revenue	4	–	21,031	–	21,039
Selling and distribution expenses		–	–	–	–
Administrative expenses		–	(1,466)	–	(8,188)
Other operating expenses		–	(81)	–	(81)
PROFIT FROM OPERATIONS		–	19,484	–	12,770
Finance costs		–	(208)	–	(208)
PROFIT BEFORE TAXATION		–	19,276	–	12,562
Income tax		–	–	–	–
PROFIT FOR THE PERIOD FROM DISCONTINUED OPERATION		–	19,276	–	12,562
Attributable to:					
Owners of the Company		–	19,276	–	12,562

10. Earnings per share

Basic earnings per share from continuing and discontinued operation

For the three-month and nine-month periods ended 30 September 2012, the calculation of basic earnings per share was based on the profit attributable to owners of the Company of approximately RMB3,169,000 and RMB28,657,000 respectively (three-month and nine-month periods ended 30 September 2011: profit of approximately RMB20,539,000 and RMB24,295,000 respectively) and the weighted average number 1,678,000,000 ordinary shares in issue for the three-month and nine-month periods ended 30 September 2012 (2011: 1,678,000,000 ordinary shares).

From continuing operation

For the three-month and nine-month periods ended 30 September 2012, the calculation of basic earnings per share from continuing operation was based on the profit attributable to owners of the Company of approximately RMB3,169,000 and RMB28,657,000 respectively (three-month and nine-month periods ended 30 September 2011: profit of approximately RMB1,263,000 and RMB11,733,000 respectively) and the denominators used are same as those detailed above for basic earnings per share from continuing and discontinued operation.

From discontinued operations

For the three-month and nine-month periods ended 30 September 2011, the calculation of basic profit per share from discontinued operations was based on the profit attributable to owners of the Company of approximately RMB19,276,000 and RMB12,562,000 respectively and the denominators used are same as those detailed above for basic earnings per share from continuing and discontinued operation.

The basic profit per share from discontinued operations is approximately RMB1.15 cents and 0.75 cents for the three-month and nine-month periods ended 30 September 2011 respectively.

From continuing and discontinued operations

Diluted earnings per share

Diluted earnings/(loss) per share for the three-month and nine-month periods ended 30 September 2012 and 2011 equals to basic earnings/(loss) per share because there were no potential dilutive ordinary shares outstanding during these periods.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Review

During the Relevant Period, the Group was principally engaged in various medicine businesses such as herbal medicine, generic drugs, transfusion and anti-tumor drugs and the research and development of modern biological pharmaceuticals (the “R&D Business”). Among which, businesses such as herbal medicine, generic drugs, transfusion and anti-tumor drugs were operated through Fuzhou Neptunus Fuyao Pharmaceutical Company Limited (“Neptunus Fuyao”) and its subsidiaries while the industrialization of biological technology products was operated by our subsidiary, Jiangsu Neptunus Bio-pharmaceutical Company Limited (“Jiangsu Neptunus”). Meanwhile, the Company dedicated itself to the R&D Business of bio-medicine and expanded the scale of the R&D of chemosynthetic anti-tumor drugs. The Company also considered operating the business of dietary supplements and foods and the purchase and sales of such products, and applying bio-technology to the fields of bio-agriculture.

Neptunus Fuyao Business

Neptunus Fuyao is a subsidiary of the Company. Neptunus Fuyao and its subsidiaries together own more than 40 production lines for 17 types of medications in dose form, all of which have passed the GMP qualifications and obtained the relevant national GMP certificates. In addition, Neptunus Fuyao and its subsidiaries together own 450 approvals in relation to the production of drugs. China’s generic drugs market is currently growing rapidly. During the Relevant Period, Neptunus Fuyao operated normally and recorded an income from principal business totaling approximately RMB405,522,000 while continuing on a steady growth trend.

Pursuant to the notice issued by the State Food and Drug Administration for the implementation of the Administrative Measures Governing the Production Quality of Pharmaceutical Products (2010 Revision) (the “New GMP”), it is required that, the production of sterile products (e.g. blood products, vaccine and injection etc.) of existing medicine manufacturers shall meet the requirements of the Administrative Measures Governing the Production Quality of Pharmaceutical Products (2010 Revision) by 31 December 2013 and the production of medicine in other categories shall meet the requirements of the Administrative Measures Governing the Production Quality of Pharmaceutical Products (2010 Revision) by 31 December 2015. Therefore, Neptunus Fuyao is considering the upgrading and enhancement of a part of the existing production equipment to meet the requirements of the New GMP. Neptunus Fuyao are currently applying to and negotiating with Fuzhou local administrative and governing departments for administrative examination and approval in relation to such upgrading and enhancement. Upgrading and enhancement as well as validation work will commence in 2013, certain production lines which involve upgrading and enhancement shall suspend production for a short period and the production will be resumed until the validation is completed. The short period of production suspension will affect normal production and supply of certain products of Neptunus Fuyao in 2013. In order to reduce or eliminate effect to operating income and profit, Neptunus Fuyao plans to implement the following measures: (1) Expand the production volume before suspending production and prepare the stocks in advance, especially the stock of bid-winning categories and high gross profit margin products; (2) well-planning for sales and to ensure the medicine supply to key markets and key clients and minimize the occurrence of shortage of medicine in the market; and (3) enhance the marketing efforts in products produced from the non-upgrading and enhancement production lines in 2013 so as to improve the sales income of medicine of this part.

As the existing production capacities for production lines of certain formulations of Neptunus Fuyao and its subsidiaries are almost fully utilised, the Group intends to construct a new production base at an industrial land in Lianjiang County, Fuzhou City through auction. The Company intends to grant RMB40,000,000 as a loan or an interest-bearing financial assistance to Neptunus Fuyao for its construction of that new production base. In addition, it is expected that the Company’s holding company, Shenzhen Neptunus Bio-engineering Co., Ltd. (“Neptunus Bio-engineering”) will grant approximately RMB80,000,000 to Neptunus Fuyao or indirectly through the Company to Neptunus Fuyao in the form of loan or interest-bearing financial assistance for its construction of the new production base. During the Relevant Period, Neptunus Bio-engineering provided interest-bearing financial assistance of RMB30,000,000 and RMB10,000,000 to Neptunus Fuyao indirectly through the Company and Shandong Neptunus Yinhe Pharmaceutical Company Limited (“Shandong Neptunus Yinhe”) for the bidding of the industrial land and preliminary work of the new production base.

As the preliminary preparation work for the construction of the new production base, the Group established three subsidiaries at Lianjiang County, Fuzhou City. The first subsidiary is Neptunus Fuyao Pharmaceutical (Lianjiang) Co., Ltd. (“Neptunus Fuyao Lianjiang”) 海王福藥製藥（連江）有限公司, which is preparing the production of chemical medicine with a registered capital of RMB50,000,000, among which RMB47,500,000 and RMB2,500,000 was contributed by Neptunus Fuyao and Neptunus Fuyao’s subsidiary Fuzhou Neptunus Jinxiang Chinese Pharmaceutical Company Limited (“Neptunus Jinxiang”) 福州海王金象中藥製藥有限公司 in cash as at 30 September 2012, which hold 95% and 5% interests in Neptunus Fuyao Lianjiang, respectively. The second subsidiary is Neptunus Jinxiang Chinese Pharmaceutical (Lianjiang) Co., Ltd. (“Neptunus Jinxiang Lianjiang”) 海王金象中藥製藥（連江）有限公司, which is preparing the production of Chinese patent medicine with a registered capital of RMB50,000,000, among which RMB1,550,000 and RMB29,450,000 was contributed by Neptunus Fuyao and Neptunus Jinxiang in cash as at 30 September 2012, which hold 5% and 95% interests in Neptunus Jinxiang Lianjiang, respectively. The third subsidiary is Lianjing Neptunus Fuyao Foods Trading Co., Ltd. (“Lianjing Neptunus Foods”) 連江縣海王福藥食品貿易有限公司. Its business scope is wholesale and retail of prepackaged foods (批發兼零售預包裝食品) with a registered capital of RMB500,000, among which RMB475,000 and RMB25,000 was contributed by Neptunus Fuyao and Neptunus Jinxiang in cash as at 30 September 2012, which hold 95% and 5% interests in Lianjing Neptunus Foods, respectively.

On 15 August 2011, the Board of the Company resolved to increase the registered capital of Neptunus Fuyao Lianjiang to RMB112,000,000 from RMB50,000,000, among which RMB106,400,000 and RMB5,600,000 were contributed by Neptunus Fuyao and Neptunus Jinxiang respectively, to fund the construction of the new production base at Lianjiang County, Fuzhou City. At present, the registered capital of both Neptunus Fuyao Lianjiang and Neptunus Jinxiang Lianjiang remained to be RMB50,000,000 and RMB50,000,000 respectively.

On 19 April 2012, Neptunus Fuyao Lianjiang and Neptunus Jinxiang Lianjiang, won two bids at the tender by the Bureau of Land Resources of Lianjiang, Fuzhou City for acquiring two pieces of land located at Aojiangyuan District, Lianjiang County, Fuzhou City at the consideration of approximately RMB22,940,000 and RMB13,280,000, respectively. The parcel number of the two pieces of land were No.敖江2012-工業-002 and No.敖江2012-工業-003, with total land area of 121,349 sq.m. and 70,258 sq.m. respectively. The relevant construction work of the new production base in Lianjiang will commence on the two pieces of land. As the progress of demolition by the local government is slower than the original plan, the land use rights grant contract has not been signed. The Company and Neptunus Fuyao are communicating with the local government department proactively in order to facilitate the local government department for completion of demolition and relocation of such piece of land.

In March 2012, Neptunus Fuyao received a letter from Fuzhou Land Development Centre (“Land Development Center”), and Land Development Center expressed its intention to acquire the industrial land of Neptunus Fuyao’s existing production base. The Group is communicating preliminarily with Land Development Center for such acquisition intention.

Recombinant Proteins and Polypeptide Drugs Business

The business scope of Jiangsu Neptunus, a wholly-owned subsidiary of the Company, includes R&D of bio-pharmaceutical products and sale of class 1 medical equipment. Jiangsu Neptunus is conducting the research and development on recombinant proteins and polypeptide drugs (including but not limited to recombinant human thymosin α 1 for injection). In October 2011, Jiangsu Neptunus conducted phase I clinical trial on recombinant human thymosin α 1 for injection, utilizing the "approval for recombinant human thymosin α 1 clinical research", an intangible asset transferred by Neptunus Pharmaceutical. Since phase I clinical trial has proceeded smoothly, the Board of the Company approved to contribute further RMB80,000,000 into Jiangsu Neptunus to increase its registered capital to RMB90,000,000. The contribution of RMB80,000,000 will be made in stages according to construction progress of Jiangsu Neptunus' Taizhou Production Base and progress of foreign exchange translation and settlement of the Company. As at the date hereof, fitting-out work of the office area of Jiangsu Neptunus' Taizhou Production Base is completed, while the production area is in the late stage of purification process. The construction is properly implemented according to project plan and the progress is smooth.

On 20 July 2012, the registered capital of Jiangsu Neptunus was increased to RMB35,000,000 and its equity interest was held by the Company as to 100%. Pursuant to requirements of regulation in relation to manufacture of Chinese medicine, Jiangsu Neptunus may not add manufacture of medicine into its business scope until the production permit is obtained.

R&D Business

Since January 2009, the Company has been focusing on the R&D Business and the expansion of the R&D Business by providing R&D services to Neptunus Bio-engineering and its subsidiaries. Due to the Company's own development in R&D Business in this Quarter, no R&D service was provided to Neptunus Bio-engineering and its subsidiaries. The Company also endeavored to seek R&D projects for new products externally, thereby exploring a new direction for its future development.

The Company entered into a technical cooperation agreement with School of Life Sciences, Jilin University on 1 March 2012 to cooperate in R&D of polypeptide and chemicals primarily by microsphere technology and to explore and establish a more advanced platform for long term drug delivery technology.

The Company entered into an academic subsidy and entrusted R&D agreement with Harbin Institute of Technology ("Harbin Institute") on 2 May 2012 for cooperative R&D of the Project ET-743 (a chemosynthetic anti-tumor drug).

With the State policy of supporting application of bio-technology to the field of agriculture, the Company selected bio-agricultural projects based on its strengths and resources in bio-technology. It also cooperated with top-class research institutions in relevant fields in China to develop competitive bio-technological products which can be commercialized as soon as possible.

Financial Review

The Group's turnover for the Relevant Period was approximately RMB405,522,000, representing an increase of 11.3% from that of approximately RMB364,321,000 in the corresponding period last year. All turnover for the Relevant Period was derived from sales income of pharmaceutical products of a subsidiary, Neptunus Fuyao. The increase in turnover was because that the sales income of Neptunus Fuyao increased by approximately 11.3% compared to the same period last year.

The Group's gross profit and gross profit margin for the Relevant Period were approximately RMB150,254,000 and 37% respectively, increasing by RMB24,315,000 and 2% respectively compared with that of the corresponding period last year. The increase in gross profit and gross profit margin were because of an increased operating income of Neptunus Fuyao during the Relevant Period.

The Group's selling and distribution expenses for the Relevant Period amounted to approximately RMB50,533,000, representing an increase of RMB6,773,000 over RMB43,760,000 of the same period last year, which was mainly due to increase in sales income resulting in corresponding increase in relevant sales and distribution expenses.

The Group's administrative expenses for the Relevant Period amounted to approximately RMB33,836,000, representing a decrease of RMB8,490,000 as compared to approximately RMB42,326,000 in the corresponding period last year. The variation of administrative expenses was caused by: (i) disposal of GSK-Neptunus which significantly reduced depreciation cost; and (ii) depreciation of RMB during the Relevant Period which rendered exchange loss of the corresponding period last year a gain.

The Group's other operating expenses for the Relevant Period amounted to approximately RMB22,147,000, increasing by approximately RMB5,511,000 compared with that of the corresponding period last year. The increase was due to the Group's increasing input in research and development which significantly increased technological R&D expenses for the Relevant Period.

The Group's finance costs for the Relevant Period was approximately RMB4,736,000, representing a decrease of approximately RMB6,406,000 from approximately RMB11,142,000 in the corresponding period last year. The decrease was primarily due to the fact that the Company repaid all the long-term loan from China Development Bank and substantial entrusted loan and financial assistance from shareholders of Neptunus Bio-engineering, and therefore no longer had obligation to pay interests accrued thereon.

The Group's profit before income tax (including discontinued operations) for the Relevant Period increased to approximately RMB49,952,000 from approximately RMB40,901,000 for the corresponding period last year, which was mainly because of (i) completion of disposal of GSK-Neptunus and the corresponding cessation of loss incurred by the Company's previous proportional shareholding; (ii) increase in turnover and gross profit of Neptunus Fuyao during the Relevant Period; and (iii) repayment of substantial borrowings and therefore a significant decrease in finance costs. As such, profit attributable to the owners of the Company amounted to approximately RMB28,657,000 for the Relevant Period, compared with that of approximately RMB24,295,000 for the corresponding period last year.

LIQUIDITY AND FINANCIAL RESOURCES

The Group usually finances its operating and investing activities with its internal financial resources and bank loans. The Group's transactions are mainly denominated in Renminbi and the Group reviews its working capital and finance requirements on a regular basis.

Banking Facilities

As at 30 September 2012, the Group's short-term bank borrowings were RMB75,000,000, all of which were short-term bank borrowings of Neptunus Fuyao. Neptunus Bio-engineering provided guarantees to Neptunus Fuyao, by which Neptunus Fuyao was granted 3 one-year short-term bank loans from the Gushan sub-branch (Fuzhou) of Agricultural Bank of China of RMB3,000,000, RMB3,000,000 and RMB3,000,000 on 24 November, 14 December and 30 December 2011 respectively, totaling RMB9,000,000, bearing interest rate of 6.232% per annum and which will be repaid on 23 November 2012, 31 December 2012 and 29 December 2012 respectively. On 23 August 2012, Neptunus Fuyao was granted a short-term loan of RMB66,000,000 from the Sanshan Sub-branch (Fuzhou) of Fujian Haixia Bank, by pledging its land use rights and buildings. This loan will be repaid on 22 August 2013 and is bearing an annual interest rate of 6.00%.

Shareholder's interest-bearing financial assistance

As at 30 September 2012, the shareholder's interest-bearing financial assistance obtained by the Company from Neptunus Bio-engineering amounted to approximately RMB30,000,000. Such shareholder's interest-bearing financial assistance is unsecured and bearing a monthly interest rate of 5%. The Company provided such fund to Neptunus Fuyao by way of shareholder's interest-bearing financial assistance for the construction plan of new production base at the same month. As of 30 September 2012, the outstanding accrued interest of shareholder's interest-bearing financial assistance from Neptunus Bio-engineering amounted to approximately RMB130,000.

As at 30 September 2012, the subsidiary of the Company obtained shareholder's financial assistance from Shandong Neptunus Yinhe, a subsidiary of Neptunus Bio-engineering, of RMB10,000,000 bearing an annual interest rate of 6%.

Shareholder's entrusted loans

Shareholder's entrusted loans obtained by the Company from Neptunus Bio-engineering as at 30 September 2012 amounted to RMB9,000,000.

The Company obtained a shareholder's entrusted loan of RMB9,000,000 from Neptunus Bio-engineering through an entrusted arrangement with a bank. This shareholder's entrusted loan is unsecured, bears an annual interest rate of 5% and is repayable on 5 April 2009. Neptunus Bio-engineering undertook that the repayment date of this entrusted loan be postponed to 5 April 2011. However, Neptunus Bio-engineering had undertaken to the Company that it would not demand repayment of the above-mentioned shareholder's entrusted loan unless and until: (1) the repayment of such shareholder's entrusted loan would not adversely affect the operations of the Company and/or its business objectives as set out in the prospectus published by the Company on 29 August 2005 (the "Prospectus"); (2) each of the independent nonexecutive Directors was of the opinion that the repayment of such shareholder's entrusted loan would not adversely affect the operations of the Company and/or the implementation of its business objectives as set out in the Prospectus, and the Company would make an announcement in respect of the decision of the independent non-executive Directors made under (2); and (3) the Company had a positive cash flow and had retained profits in the relevant financial year.

On 26 March 2012, the Company obtained another shareholder's entrusted loan of RMB30,000,000 from Neptunus Bio-engineering through an entrusted loan agreement with Bank of Hangzhou. This shareholder's entrusted loan is unsecured, bears a monthly interest of 0.5% and is repayable on 26 June 2012. The Company granted the proceeds from the entrusted loan to Neptunus Fuyao by way of shareholder's interest-bearing financial assistance for tendering for the land used for the new production base in Lianjiang in April 2012. The Company has repaid all the principal and interest of such entrusted loans in September 2012.

Net current assets

As at 30 September 2012, the Group had net current assets of approximately RMB183,636,000. Current assets comprised cash and cash equivalents of approximately RMB249,688,000, pledged bank deposits of approximately RMB23,907,000, inventories of approximately RMB121,018,000, and trade and other receivables of approximately RMB115,187,000. Current liabilities comprised trade and bills payables of approximately RMB129,110,000, interest-bearing bank borrowings to be repaid within one year of approximately RMB75,000,000, tax payable of approximately RMB5,657,000, amounts due to related companies of approximately RMB59,431,000, and other payables of approximately RMB56,966,000. The net current assets was broadly the same as compared with that of approximately RMB185,448,000 as at 31 December 2011.

Foreign Currency Risk

During the Relevant Period, the Group's operating revenue, major selling costs and capital expenditure were denominated in RMB. Proceeds from the issue of 189,330,000 new H shares of approximately HK\$164,252,000 were not fully translated into RMB in accordance with national foreign exchange regulations. As at 30 September 2012, approximately 23,863,000 was still not translated into RMB. In addition, in the consideration from disposal of 51% equity interest in GSK-Neptunus, a jointly controlled entity, which was denominated in USD, approximately USD11,194,000 was still not translated into RMB as at 30 September 2012. As such, the exchange rate fluctuation of Hong Kong dollars and USD against RMB may affect the Group's profit for the Relevant Period. However, the foreign currency risk facing the Group is limited. Currently, the Group has not adopted any financial instrument for hedging purposes.

Contingent Liability

As at 30 September 2012, the Group had no significant contingent liability.

INTERESTS AND SHORT POSITIONS OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVES IN THE LISTED SECURITIES

As far as the Directors or supervisors of the Company are aware, as at 30 September 2012, the interests and short positions of the Directors, supervisors and chief executives of the Company in the shares, underlying shares and debentures of the Company and its associated corporations which were required to be notified to the Company and the Stock Exchange pursuant to Part XV of the Securities and Futures Ordinance (the "SFO") (including interests which they were taken or deemed to have under such provisions of the SFO), or were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or were required, pursuant to the "required standard of dealings" for directors as set out in Rule 5.46 of the GEM Listing Rules to be notified to the Company and the Stock Exchange or had otherwise notified to the Company were as follows:

Long positions in the shares of the Company:

Director/supervisor	Capacity	Type of Interests	Number of domestic shares held	Approximate percentage of all the domestic shares	Approximate percentage of the Company's issued share capital
Mr. Chai Xiang Dong (Note 1)	Beneficial owner	Personal	30,561,000	2.44%	1.82%
Mr. Yu Jun (Note 2)	Beneficial owner	Personal	1,014,000	0.08%	0.06%

Notes:

1 Executive director and general manager of the Company

2 Supervisor and employee of the Company

Long positions in shares of associated corporations of the Company:

Director	Capacity	Type of Interests	Name of associated corporation	Number of shares held in associated corporation	Approximate percentage of the associated corporation's issued share capital
Mr. Zhang Feng (Note (a))	Beneficial owner	Personal	Neptunus Bio-engineering	532,437	0.08%
Mr. Liu Zhan Jun (Note (b))	Beneficial owner	Personal	Neptunus Bio-engineering	266,217	0.04%
Ms. Yu Lin (Note (c))	Beneficial owner	Personal	Neptunus Bio-engineering	79,864	0.01%

Notes:

- (a) Mr. Zhang Feng, who is the deputy chairman of the board of directors of Neptunus Bio-engineering, was beneficially interested in approximately 0.08% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 71.67% of the entire issued share capital of the Company, of which 70.38% was directly held and 1.29% was indirectly held through Shenzhen Neptunus Oriental Investment Co., Ltd..
- (b) Mr. Liu Zhan Jun, who is a director and president of Neptunus Bio-engineering, was beneficially interested in approximately 0.04% of the entire issued share capital of Neptunus Bio-engineering, the Company's controlling shareholder, which in turn held directly and indirectly the beneficial interest in approximately 71.67% of the entire issued share capital of the Company, of which 70.38% was directly held and 1.29% was indirectly held through Shenzhen Neptunus Oriental Investment Co., Ltd..
- (c) Ms. Yu Lin, who is a director and vice-president of Neptunus Bio-engineering, was beneficially interested in approximately 0.01% of the entire issued share capital of Neptunus Bio-engineering, which in turn held directly and indirectly the beneficial interest in approximately 71.67% of the entire issued share capital of the Company, of which 70.38% was directly held and 1.29% was indirectly held through Shenzhen Neptunus Oriental Investment Co., Ltd..

Save as disclosed above, as at 30 September 2012, none of the Directors, supervisors or chief executives of the Company nor their respective associates held any interests or short positions in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept under section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the "required standard of dealings" for directors as set out in Rule 5.46 of the GEM Listing Rules.

SHARE OPTION SCHEME, CONVERTIBLE SECURITIES AND WARRANTS

Up to 30 September 2012, the Company and its subsidiaries have not adopted any share option scheme and have not granted any option, convertible securities, warrants or other similar rights.

DIRECTORS' AND SUPERVISORS' SHARE OPTIONS, WARRANTS OR CONVERTIBLE BONDS

At any time during the Relevant Period, none of the Directors or supervisors of the Company or their respective spouse or minor children were granted any share options, warrants or convertible bonds of the Company, its subsidiaries or associated corporation.

SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SHARES AND UNDERLYING SHARES

So far as the Directors and supervisors of the Company are aware, as at 30 September 2012, the interests and/or short positions held by shareholders (not being a director, a supervisor or a chief executive of the Company) in shares or underlying shares of the Company which were required to be entered in the register pursuant to Section 336 of the SFO or had otherwise notified to the Company were as follows:

Long positions in the shares of the Company:

Name of substantial shareholders	Capacity	Number of domestic shares held	Approximate percentage of all the domestic shares	Approximate percentage of the Company's issued share capital
Neptunus Bio-engineering (Note (a))	Beneficial owner	1,181,000,000	94.33%	70.38%
	Interest in controlled corporation	21,650,000	1.73%	1.29%
Neptunus Group (Note (b))	Interest in controlled corporation	1,202,650,000	96.06%	71.67%
Ankeen Enterprises Limited ("Ankeen Enterprises") (Note (c))	Interest in controlled corporation	1,202,650,000	96.06%	71.67%
Ms. Wang Jin Song (Note (d))	Interest in controlled corporation	1,202,650,000	96.06%	71.67%

Notes:

- (a) Neptunus Bio-engineering was deemed to be interested in the 21,650,000 domestic shares of the Company held by Shenzhen Neptunus Oriental Investment Co., Ltd. ("Neptunus Oriental") as the entire issued share capital of Neptunus Oriental was beneficially owned by Neptunus Bio-engineering. Neptunus Bio-engineering was also directly interested in 1,181,000,000 domestic shares of the Company. Therefore, Neptunus Bio-engineering was directly and indirectly interested in 1,202,650,000 domestic shares of the Company.
- (b) Neptunus Group was deemed to be interested in the 1,202,650,000 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Neptunus Group was beneficially interested in approximately 27.66% of the entire issued share capital of Neptunus Bio-engineering.
- (c) Ankeen Enterprises was deemed to be interested in 1,202,650,000 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Ankeen Enterprises was beneficially interested in approximately 41.90% of the entire issued share capital of Neptunus Group, which in turn was beneficially interested in approximately 27.66% of the entire issued share capital of Neptunus Bio-engineering.
- (d) Ms. Wang Jin Song ("Ms. Wang") was deemed to be interested in 1,202,650,000 domestic shares of the Company, which relate to the same parcel of shares referred to in note (a) above, held by Neptunus Bio-engineering as Ms. Wang was beneficially interested in 85% of the entire issued share capital of Ankeen Enterprises, which in turn was beneficially interested in approximately 41.9% of the entire issued share capital of Neptunus Group, which in turn was beneficially interested in approximately 27.66% of the entire issued share capital of Neptunus Bio-engineering.

Save as disclosed above, the Directors and supervisors of the Company are not aware of any other persons (except the Directors, supervisors or chief executives of the Company) who held any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept under Section 336 of the SFO as at 30 September 2012.

PURCHASE, SALE OR REDEMPTION OF THE LISTED SECURITIES OF THE COMPANY

The Company and its subsidiaries did not purchase, sell or redeem any of the Company's listed securities during the Relevant Period. The Company and its subsidiaries also did not redeem, purchase or cancel any of their redeemable securities.

COMPETING INTERESTS

On 21 August 2005, Neptunus Bio-engineering, the controlling shareholder of the Company, entered into an agreement with the Company, in relation to non-competition undertakings and priority investment rights (the "Non-Competition Undertakings"), pursuant to which Neptunus Bio-engineering had undertaken to the Company and its associates that, inter alia, as long as the securities of the Company are listed on GEM:

1. it will not, and will procure its associates not to whether within or outside the PRC, directly or indirectly or by any means, participate in or operate any business which may constitute direct or indirect competition with the business operated by the Company from time to time, or produce any products, the usage of which is the same as or similar to that of the products of the Company (other than those indirectly held as a result of the equity interest in any listed company or its subsidiaries); and

2. it will not, and will procure its associates not to hold any interest, whether within or outside the PRC, in any company or organization (directly or indirectly, other than indirectly held as a result of its equity interest in any listed company or its subsidiaries) when the business of such company or organisation will (or may) compete directly or indirectly with the business of the Company.

Pursuant to the Non-Competition Undertakings, during the term of such Undertakings, when Neptunus Bio-engineering or its associates enter into any negotiations, within or outside the PRC, in relation to any new investment project which may compete with the existing and future business of the Company, the Company shall have a preferential right of investment in such investment projects.

CODE OF CONDUCT REGARDING SECURITIES TRANSACTIONS BY DIRECTORS

During the Relevant Period, the Company has adopted a code of conduct regarding securities transactions by Directors on terms no less exacting than the “required standard of dealings” as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. Having made specific enquiry of all the Directors, all the Directors confirmed that there is no violation by the Directors on the “required standard of dealings” and the Company’s code of conduct regarding securities transactions by the Directors during the Relevant Period.

AUDIT COMMITTEE

The Company established an Audit Committee (the “Audit Committee”) on 21 August 2005. The primary duties of the Audit Committee are to review the Company’s annual report and financial statements, half-yearly reports and quarterly reports, and to provide suggestions and opinions thereon to the Board. In addition, the Audit Committee members will also meet with the management to review the accounting principles and practices adopted by the Company and to discuss matters relating to the auditing, internal control system and financial reporting process of the Company. The Audit Committee comprises one non-executive Director, namely Ms. Yu Lin and two independent non-executive Directors, namely Mr. Yick Wing Fat, Simon and Mr. Poon Ka Yeung. Mr. Yick Wing Fat, Simon is the chairman of the Audit Committee.

The Audit Committee has reviewed the unaudited results of the Group for the Relevant Period.

COMPLIANCE WITH THE CODE ON CORPORATE GOVERNANCE PRACTICE

As the Directors are aware, during the Relevant Period, the Company has complied with the requirements under the “Corporate Governance Code and Corporate Governance Report” set out in Appendix 15 to the GEM Listing Rules. The Board will continue to enhance the standard of corporate governance of the Company to ensure that the Company will operate its business in an honourable and responsible manner.

On behalf of the Board

Shenzhen Neptunus Interlong Bio-technique Company Limited

Zhang Feng

Chairman

Shenzhen, the PRC, 8 November 2012

As at the date of this announcement, the executive Directors of the Company are Mr. Zhang Feng, Mr. Chai Xiang Dong and Mr. Xu Yan He; the non-executive Directors are Mr. Liu Zhan Jun, Ms. Yu Lin and Mr. Ren De Quan; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Huang Yao Wen.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the website of the Company at www.interlong.com.

* For identification purpose only